Description
Although billions have been spent on oseltamivir in the face of pandemic influenza, the team updating the Cochrane review of neuraminidase inhibitors in healthy adults found that the public evidence base for this global public health drug was fragmented and inconsistent. Peter Doshi tells the storyCitation
Doshi P. (2009). Neuraminidase inhibitors--the story behind the Cochrane review. BMJ 2009;339:b5164. DOI: https://doi.org/10.1136/bmj.b5164Keyword
neuraminidase inhibitorsTamiflu
public health policy
drug efficacy
Systematic reviews (Medical research)
Influenza, Human--drug therapy
Oseltamivir
Identifier to cite or link to this item
http://hdl.handle.net/10713/6612ae974a485f413a2113503eed53cd6c53
10.1136/bmj.b5164
Scopus Count
Collections
Related articles
- The truth about Tamiflu? Neuraminidase inhibitors in pandemic A/H1N1 flu.
- Authors: Weber JT, Nicoll A, Bridges CB, Ciancio BC
- Issue date: 2010 Jan 13
- Oseltamivir resistance: what does it mean clinically?
- Authors: Baum SG
- Issue date: 2009 Dec 15
- Global transmission of oseltamivir-resistant influenza.
- Authors: Moscona A
- Issue date: 2009 Mar 5
- Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
- Authors: Kawai N, Ikematsu H, Hirotsu N, Maeda T, Kawashima T, Tanaka O, Yamauchi S, Kawamura K, Matsuura S, Nishimura M, Iwaki N, Kashiwagi S
- Issue date: 2009 Dec 15
- Why don't we have all the evidence on oseltamivir?
- Authors: Godlee F, Clarke M
- Issue date: 2009 Dec 8